<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02521870</url>
  </required_header>
  <id_info>
    <org_study_id>DV3-MEL-01</org_study_id>
    <secondary_id>Keynote 184</secondary_id>
    <nct_id>NCT02521870</nct_id>
  </id_info>
  <brief_title>A Trial of Intratumoral Injections of SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma or Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma</brief_title>
  <official_title>A Phase 1b/2, Open-label, Multicenter, Dose-escalation and Expansion Trial of Intratumoral SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma or Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dynavax Technologies Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Dynavax Technologies Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase 1b/2, open-label, multicenter trial designed to evaluate the safety,
      tolerability, biologic activity, and preliminary efficacy of intratumoral SD 101 injections
      in combination with intravenous pembrolizumab in patients with metastatic melanoma or
      recurrent or metastatic head and neck squamous cell carcinoma (HNSCC).

      Phase 1 of this trial is a modified 3+3 dose escalation study evaluating escalating or
      intermediate dose levels of SD-101 given with a fixed dose of pembrolizumab in patients with
      metastatic melanoma.

      Phase 2 of this study will consist of 4 expansion cohorts to further evaluate the efficacy
      and safety of SD-101 given in combination with pembrolizumab in specific melanoma and HNSCC
      populations: For each of the indications in melanoma and HNSCC 2 separate cohorts will be
      recruited, those who are anti-programmed death receptor-1/ligand 1 (anti-PD-1/L1) therapy
      naïve and those who have progressive disease (PD) while receiving anti-PD-1/L1 therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will be conducted in two parts.

      Phase 1b is dose escalation in which patients are tested with SD-101 at various doses in
      combination with 200 mg pembrolizumab in patients with metastatic melanoma.

      Phase 2 will consist of 4 expansion cohorts to evaluate the efficacy and safety of SD-101
      given in combination with 200 mg pembrolizumab in specific melanoma populations and recurrent
      or metastatic HNSCC.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2015</start_date>
  <completion_date type="Anticipated">February 2020</completion_date>
  <primary_completion_date type="Anticipated">February 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase 1b - Incidence of dose-limiting toxicities (DLTs).</measure>
    <time_frame>Day 29</time_frame>
    <description>DLTs evaluated through 7 days after last dose</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 2 To assess the tumor response both locally and systemically of injected lesions, non-injected lesions, and all lesions.</measure>
    <time_frame>Day 743</time_frame>
    <description>Evaluated through Day 743</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Phase 2 - Incidence of injection-site reactions, adverse events (AEs) and serious adverse events (SAEs)</measure>
    <time_frame>Day 743</time_frame>
    <description>Evaluated through Day 743</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2 - Time to objective response (TOR) per RECIST 1.1</measure>
    <time_frame>Day 743</time_frame>
    <description>Evaluated through Day 743</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2 - Duration of response per RECIST 1.1</measure>
    <time_frame>Day 743</time_frame>
    <description>Evaluated through Day 743</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2 - Duration of radiographic progression-free survival (PFS) per RECIST 1.1</measure>
    <time_frame>Day 743</time_frame>
    <description>Evaluated through Day 743</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Metastatic Melanoma</condition>
  <condition>Head Neck Cancer</condition>
  <arm_group>
    <arm_group_label>Dose Escalation Phase 1b</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Determine the MTD of escalating doses of SD-101(1) administered in combination with pembrolizumab.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Expansion Phase 2 (1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Determine the safety and efficacy of SD-101(2) and pembrolizumab in anti-PD-1/L1 therapy naïve patients with recurrent or metastatic melanoma.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Expansion Phase 2 (2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Determine the safety and efficacy of SD-101(2) and pembrolizumab in anti-PD-1/L1 therapy progressing patients with recurrent or metastatic melanoma.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Expansion Phase 2 (3)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Determine the safety and efficacy of SD-101(2) and pembrolizumab in anti-PD-1/L1 therapy naïve patients with recurrent head and neck squamous cell carcinoma.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Expansion Phase 2 (4)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Determine the safety and efficacy of SD-101(2) and pembrolizumab in anti-PD-1/L1 therapy progressing patients with recurrent head and neck squamous cell carcinoma.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SD-101(1)</intervention_name>
    <description>SD-101 administered intratumorally at escalating doses (up to 11 doses)</description>
    <arm_group_label>Dose Escalation Phase 1b</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>Pembrolizumab administered intravenously, 200 mg Q3W for two years (up to 35 doses)</description>
    <arm_group_label>Dose Escalation Phase 1b</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SD-101(2)</intervention_name>
    <description>SD-101 administered intratumorally (up to 22 doses)</description>
    <arm_group_label>Dose Expansion Phase 2 (1)</arm_group_label>
    <arm_group_label>Dose Expansion Phase 2 (2)</arm_group_label>
    <arm_group_label>Dose Expansion Phase 2 (3)</arm_group_label>
    <arm_group_label>Dose Expansion Phase 2 (4)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>Pembrolizumab administered intravenously, 200mg Q3W for two years (up to 35 doses)</description>
    <arm_group_label>Dose Expansion Phase 2 (1)</arm_group_label>
    <arm_group_label>Dose Expansion Phase 2 (2)</arm_group_label>
    <arm_group_label>Dose Expansion Phase 2 (3)</arm_group_label>
    <arm_group_label>Dose Expansion Phase 2 (4)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria: Phase 2 Melanoma patients

          -  Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0 or 1.

          -  Life expectancy of at least 6 months.

          -  Provide tissue for PD-L1 biomarker analysis from a newly obtained biopsy obtained
             within 28 days of enrollment. Archival tissue within 3 months of screening is
             acceptable.

          -  Histologically or cytologically confirmed unresectable in-transit (stage IIIc) or
             metastatic (stage IV) melanoma.

          -  At least 2 sites of measurable disease of which 1 must be palpable or visualized by
             ultrasound and easily accessible to multiple intratumoral injections. The injected
             lesions must qualify as a measurable target lesion per RECIST 1.1.

          -  Metastatic melanoma patients with progressive disease (PD) while receiving
             anti-PD-1/L1 therapy must have documented PD per RECIST 1.1 while receiving a prior
             anti-PD-1/L1 therapy and must have received a prior anti-PD-1/L1 agent within 12 weeks
             of study enrollment.

        Inclusion Criteria: Phase 2 HNSCC patients

          -  Histologically or cytologically confirmed recurrent or metastatic HNSCC that could not
             be treated with curative intent.

          -  Have at least 1 measurable site of disease (target lesion per RECIST 1.1, which must
             be accessible and amenable to multiple intratumoral injections. If superficial, the
             lesion must measure at least 10 mm in diameter, measured by calipers, and be
             documented photographically.

          -  Recurrent or metastatic HNSCC patients with PD while receiving anti-PD-1/L1 therapy
             must have documented PD per RECIST 1.1 while receiving anti-PD-1/L1 therapy and must
             have received anti-PD-1/L1 agent within 12 weeks of study enrollment.

        Exclusion Criteria: (Phase 2 Melanoma and HNSCC patients)

          -  Received chemotherapy, systemic radiotherapy, or biological cancer therapy (except
             anti-PD-1/L1 therapy) within 3 weeks prior to study enrollment.

          -  Received small molecule inhibitor targeted therapy, such as tyrosine kinase
             inhibitors, within 2 weeks prior to study enrollment.

          -  Diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other
             form of immunosuppressive therapy (including immune modulators or systemic
             corticosteroids) within 7 days prior to study enrollment

          -  Is expected to require any other form of anti-cancer therapy while in the trial.

          -  Positive for hepatitis B, hepatitis C, or human immunodeficiency virus (HIV).

          -  History of or current uveal or ocular melanoma.

          -  Active infection including cytomegalovirus.

          -  Active autoimmune disease requiring systemic treatment in the past 2 years or a
             disease that requires immunosuppressive medication. Replacement therapy is not
             considered a form of systemic treatment.

          -  Current pneumonitis or history of (non-infectious) pneumonitis that required steroids.

          -  Known active central nervous system metastases or carcinomatous meningitis.

          -  Use of any investigational agent within the last 28 days prior to study enrollment.

          -  Has received a live-virus vaccination within 30 days of planned treatment start.
             Seasonal flu vaccines that do not contain live virus are permitted.

          -  Any known additional malignancy that is progressing or requires active treatment,
             except for melanoma and HNSCC.

        Exclusion Criteria (Phase 2, Melanoma Expansion Cohort 1 only)

          -  Any prior combination therapy targeting immunoregulatory receptors or mechanisms and
             an anti-PD-1/L1 agent or an investigational agent targeting immunoregulatory receptors

          -  Prior therapy with an anti PD 1/L1 agent

          -  Exclusion Criteria: (Phase 2, Melanoma Expansion Cohort 2 only)

          -  Any prior combination therapy involving T-VEC or other agents given by intratumoral
             injection and an anti-PD-1/L1 inhibitor.

        Exclusion Criteria: (Phase 2, HNSCC Expansion Cohort 3 only)

          -  Prior therapy with an investigational agent targeting immunoregulatory receptors or
             mechanisms (exception is prior ipilimumab, which is allowed)

          -  Prior therapy with an anti PD 1/L1 agent

          -  Require treatment on anticoagulation therapy.

        Exclusion Criteria (Phase 2, HNSCC Expansion Cohort 4 only)

          -  Any prior combination therapy involving agents given by intratumoral injection and an
             anti-PD-1/L1 inhibitor.

          -  Require treatment on anticoagulation therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Antoni Ribas, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UCLA School of Medicine (Melanoma)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ezra Cohen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UCSD Moores Cancer Center (HNSCC)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Erick Gamelin, MD</last_name>
    <phone>510-665-0470</phone>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Robert Janssen, MD</last_name>
    <phone>510-665-0414</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Alabama School of Medicine</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Alabama</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Arizona Cancer Center</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85721</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisa Slayton</last_name>
      <phone>520-694-9057</phone>
      <email>Lslayton@uacc.arizona.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of California, Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean Kim</last_name>
      <phone>310-794-2464</phone>
      <email>jeank@mednet.ucla.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Stanford Hospitals and Clinics</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jee Min Lee</last_name>
      <phone>650-497-5240</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of California, San Diego</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Parissa Shayesteh</last_name>
      <phone>858-822-5368</phone>
      <email>pshayesteh@ucsd.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>UCSF</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94158</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>415-502-3081</phone>
      <email>Kyusun.Cha@ucsf.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michelle Carr</last_name>
      <phone>720-848-7135</phone>
      <email>Michelle.L2.Carr@ucdenver.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Comprehensive Cancer Center</name>
      <address>
        <city>Miami Beach</city>
        <state>Florida</state>
        <zip>33140</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jose Lutzky, MD</last_name>
      <phone>305-535-3300</phone>
      <email>Jose.lutzky@msmc.com</email>
    </contact>
    <contact_backup>
      <last_name>Yvonne Enriquez-Nunez</last_name>
      <phone>305-674-2625</phone>
      <email>Yenrique@msmc.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Georgia Cancer Specialists</name>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <zip>30033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sally Haislip</last_name>
      <phone>770-496-9457</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60208</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sunandana Chandra</last_name>
      <email>Sunandana.chandra@nm.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Indiana University Simon Cancer Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>University of Iowa Healthcare</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Teena Davis VanDaele</last_name>
      <phone>319-467-5834</phone>
      <email>teena-vandaele@uiowa.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christopher Lao</last_name>
      <phone>734-647-8906</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Barbara Ann Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>313-576-8994</phone>
      <email>wolgasta@karmanos.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Nebraska Cancer Specialists, Midwest Cancer Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68130</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Atlantic Health</name>
      <address>
        <city>Morristown</city>
        <state>New Jersey</state>
        <zip>07962</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>716-845-5804</phone>
      <email>suzanne.stack@roswellpark.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Levine Cancer Institute</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ashley Franklin</last_name>
      <phone>980-442-2315</phone>
      <email>Ashley.Franklin@carolinashealthcare.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Christ Hospital</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>University Hospitals Cleveland Medical Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Univ. of Okalhoma Health Sciences Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ingrid Block</last_name>
      <phone>405-271-8777</phone>
      <email>Ingrid-block@ouhsc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Providence Portland Medical Center</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>The Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Penn State Hershey Medical Center</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Hallman</last_name>
      <phone>717-531-5471</phone>
      <email>jhallman@pennstatehealth.psu.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mary Crowley Cancer Research Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75230</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amy Jordon</last_name>
      <phone>972-566-3000</phone>
      <email>referral@marycrowley.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Texas, San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Huntsman Cancer institute</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jacqueline Richards</last_name>
      <phone>801-587-4433</phone>
      <email>Jacqueline.Richards@hci.utah.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Inova Schar Cancer Institute</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kelly Jeffords</last_name>
      <phone>703-970-6548</phone>
      <email>Kelly.Jeffords@inova.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>West Virginia University</name>
      <address>
        <city>Morgantown</city>
        <state>West Virginia</state>
        <zip>26506</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carla Ross</last_name>
      <phone>304-581-1158</phone>
      <email>CJROSS@hsc.wvu.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Liverpool Hospital</name>
      <address>
        <city>Liverpool</city>
        <state>New South Wales</state>
        <zip>2170</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Melanoma Institute</name>
      <address>
        <city>North Sydney</city>
        <state>New South Wales</state>
        <zip>2065</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Tweed Hospital</name>
      <address>
        <city>Tweed Heads</city>
        <state>New South Wales</state>
        <zip>2485</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ashford Cancer Centre Research</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5037</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Affinity Clinical Research Services</name>
      <address>
        <city>Perth</city>
        <state>Western Australia</state>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Charité - Universitätsmedizin Berlin</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Klinikum Buxtehude</name>
      <address>
        <city>Buxtehude</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Dresden</name>
      <address>
        <city>Dresden</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospital Frankfurt</name>
      <address>
        <city>Frankfurt</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover</name>
      <address>
        <city>Hannover</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>HNO-Universitätsklinik Jena</name>
      <address>
        <city>Jena</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätshautklinik Magdeburg</name>
      <address>
        <city>Magdeburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Regensburg</name>
      <address>
        <city>Regensburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Tübingen</name>
      <address>
        <city>Tubingen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Auckland City Hospital</name>
      <address>
        <city>Auckland</city>
        <zip>1023</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Christchurch Hospital</name>
      <address>
        <city>Christchurch</city>
        <zip>4710</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Waikato Hospital</name>
      <address>
        <city>Hamilton</city>
        <zip>3204</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Germany</country>
    <country>New Zealand</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 30, 2015</study_first_submitted>
  <study_first_submitted_qc>August 10, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 13, 2015</study_first_posted>
  <last_update_submitted>May 17, 2018</last_update_submitted>
  <last_update_submitted_qc>May 17, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 21, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Skin Cancer</keyword>
  <keyword>Skin Tumors</keyword>
  <keyword>Head and Neck Squamous Cell Carcinoma</keyword>
  <keyword>Cancer Immunotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Melanoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pembrolizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Data will be shared under guidance of the New Rule - FDAAA 801 eff. Jan 2017. 3/2017 - additional changes forthcoming.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

